Liposomal Resiquimod for Enhanced Immunotherapy of Peritoneal Metastases of Colorectal Cancer

Colorectal cancer with peritoneal metastases is currently treated by cytoreductive surgery and locoregional chemotherapeutics. This standard treatment is associated with high morbidity, mortality, and recurrence rate. To augment the existing therapy, we developed a liposome-based delivery system con...

Descripción completa

Detalles Bibliográficos
Autores principales: Pauli, Griffin, Chao, Po-Han, Qin, Zhu, Böttger, Roland, Lee, Suen Ern, Li, Shyh-Dar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8540734/
https://www.ncbi.nlm.nih.gov/pubmed/34683992
http://dx.doi.org/10.3390/pharmaceutics13101696

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8540734/
https://www.ncbi.nlm.nih.gov/pubmed/34683992
http://dx.doi.org/10.3390/pharmaceutics13101696

Ejemplares similares